Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • JnJ to pay Rs 230...

    JnJ to pay Rs 230 crore fine for not passing GST rate cut benefits to customers

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-28T16:03:45+05:30  |  Updated On 28 Dec 2019 4:03 PM IST

    New Delhi: Healthcare major, Johnson and Johnson (JnJ) recently landed in soup after the National Anti-profiteering Authority (NAA) found that its local unit made a profit to the tune of Rs 230.4 crores by not passing the benefit of goods and services tax(GST)cut on some products. The Authority directed the firm to deposit the penalty amount in a consumer welfare fund within three-months time.


    Notably, in November 2017, the GST Council announced one of its biggest rounds of tax rate cuts so far when it moved 178 items from the 28 per cent slab to 18 per cent slab. Later, the DGAP looked into several complaints of profiteering by consumer goods manufacturers and their dealers. One such inquiry was conducted by the Authority between November 2017 and December 2018.


    After the inquiry, the Director-General of Anti-profiteering (DGAP), an investing arm of NAA, concluded that despite the reduction in the GST rate from 28% to 18% on some of their products, the company had net higher sales realisation, primarily owing to increase in the base price of products. In other words, JnJ had raised the base price of certain products when the tax rate was cut.


    “The DGAP concluded that the amount of net higher sales realization due to increase in the base prices of the impacted products despite the reduction of GST rate from 28% to 18% or in other words, the profiteered amount, came to Rs 230.4 crore,” the NAA order said.


    The authority noted, "the respondent (J&J) denied the benefit of tax reduction to customers in contravention of Section 17(1) of CGST Act, 2017 and has thus profiteered as per the explanation attached to Section 171 of the Act."


    The Authority further observed that the methodology adopted by JnJ to pass on GST rate-cut benefit was 'unreasonable, arbitrary, and incorrect, and hence cannot be accepted'.


    As per the anti-profiteering rules under GST, "benefits of input tax credit should have been passed on to the recipient by way of commensurate reduction in prices."


    Subsequently, the order signed by B.N. Sharma, Chairman, NAA was issued directing the firm to deposit the amount along with 18 per cent interest in the national consumer welfare fund.

    dgpagoods n services taxGSTgst benefitsGST Councilgst rate cutsJnJjnj fineJohnsonJohnson and JohnsonNAAnational antiprofiteering authoritypharmapharma company

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok